Manbro Industries Ltd
Incorporated in 1992, Manbro Industries Ltd is in the business of Food & Beverages[1]
- Market Cap ₹ 242 Cr.
- Current Price ₹ 418
- High / Low ₹ 1,300 / 392
- Stock P/E
- Book Value ₹ 75.8
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.51 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 97% |
| 3 Years: | 81% |
| 1 Year: | -64% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Nov - The Company has published the Statement of Standalone and Consolidated Financial results for the Quarter and Half Year ended 30th September 2025.
-
Un- Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30Th September 2025.
14 Nov - Board approved Q2 Sep 30, 2025 results; raised ₹415.19M; ₹325M invested; acquired 51% Shivam Pipe, 26% KD Ecosystem.
-
Board Meeting Outcome for Outcome Of Board Meeting And Intimation Pursuant To Regulation 30 Of SEBI (LODR) Regulations 2015.
14 Nov - Approved unaudited Q2 (Sept 30, 2025) results; acquired 51% Shivam Pipe, 26% KD Ecosystem; Rs.325.00m invested.
-
Board Meeting Intimation for Prior Intimation Of Board Meeting
11 Nov - Board meeting 14 Nov 2025 to approve Q2 results, name change, and ₹10 to Re.1 share split, trading window details included, reopening 16 Nov 2025
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Oct - Certificate under Reg 74(5) confirming dematerialization processing for quarter ended 30 Sep 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Objects:[1]
MIL is engaged in importing, exporting, trading, distributing, and manufacturing a wide range of products across the following categories:
a) Food & Beverages: Snacks, dairy, bakery items, beverages (aerated water, mineral water, syrups, soft drinks, fruit drinks), whole grains, pulses, rice, spices, organic products, spice mixes, oleoresins, essential oils, freeze-dried foods, and preserved vegetables and herbs.
b) Preservation & Processing: Canning, preserving, and manufacturing of pickles, chutneys, spice powders (turmeric, chili, coriander, cumin), vinegars, ketchups, juices, custard powders, beverages, gelatins, essences, ice creams, and other edible items.
c) Pharmaceuticals & Healthcare: Antibiotics, medicines, ayurvedic and dietary supplements, medicinal goods (surgical instruments, contraceptives, cosmetics, soaps, oils), veterinary medicines, and hospital requisites.
d) Packaging & Processing: Vialling, bottling, repacking, and processing of tablets, capsules, syrups, injections, ointments, and related products.